For Long COVID, targeting G9a might also help alleviate lingering symptoms by potentially reversing the virus's long-term impacts on our bodies.
Based on a recent dissertation:
https://www.cell.com/cell-chemical-biology/abstract/S2451-94...
A novel G9a inhibitor has been identified that has been seen helpful for Alzheimer's as well:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690335/
> Thus, in contrast to existing AD therapies that only slow one symptom (e.g., cognitive decline) targeting AD-activated G9a by the brain-penetrant drug MS1262 showed multifaceted effects that relieve all AD symptoms with minimum side effect.
For Long COVID, targeting G9a might also help alleviate lingering symptoms by potentially reversing the virus's long-term impacts on our bodies.
Based on a recent dissertation:
https://www.cell.com/cell-chemical-biology/abstract/S2451-94...
A novel G9a inhibitor has been identified that has been seen helpful for Alzheimer's as well:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690335/
> Thus, in contrast to existing AD therapies that only slow one symptom (e.g., cognitive decline) targeting AD-activated G9a by the brain-penetrant drug MS1262 showed multifaceted effects that relieve all AD symptoms with minimum side effect.